NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 110 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,123,240 | +9.8% | 1,984,336 | +165.8% | 0.23% | -53.3% |
| Q2 2023 | $1,933,886 | -36.5% | 746,674 | 0.0% | 0.50% | -81.4% |
| Q1 2023 | $3,046,430 | -18.7% | 746,674 | 0.0% | 2.67% | -23.8% |
| Q4 2022 | $3,748,303 | -61.6% | 746,674 | 0.0% | 3.51% | -61.3% |
| Q3 2022 | $9,766,000 | +2.0% | 746,674 | 0.0% | 9.07% | +11.4% |
| Q2 2022 | $9,572,000 | -15.9% | 746,674 | 0.0% | 8.14% | +23.0% |
| Q1 2022 | $11,387,000 | -13.9% | 746,674 | 0.0% | 6.62% | -12.0% |
| Q4 2021 | $13,224,000 | -24.4% | 746,674 | -10.3% | 7.52% | -11.6% |
| Q3 2021 | $17,494,000 | -40.6% | 832,274 | -44.3% | 8.50% | -11.0% |
| Q2 2021 | $29,449,000 | -32.2% | 1,493,349 | 0.0% | 9.56% | -34.2% |
| Q1 2021 | $43,412,000 | -31.2% | 1,493,349 | -28.3% | 14.52% | +8.7% |
| Q4 2020 | $63,133,000 | – | 2,083,602 | – | 13.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |